History

  • 12 UBP received approval from TFDA for UB-421 (anti CD4 mAb) phase II, proof of concept, trial in HAART stabilized HIV patients for functional cure.
    12 UBP received approval from TFDA for UB-221(anti-IgE mAb) phase I clinical trial.
    11 UBP filed IND for UB-621(anti-HSV-gD mAb) phase II clinical trial with US FDA.
    10 UBP filed IND with TFDA for UB-421 phase II, proof of concept trial in HAART stabilized HIV patients for functional cure.
    08/09 UBP chose to delist the company’s shares on the Taiwan Emerging Stock Market of the Taipei Exchange and to relist on a foreign stock exchange.
    07 UBP’s third generation Monoclonal anti-IgE antibody was awarded the Bronze Medal by Taipei City Government in its 2018 Annual Biotechnology Forum.
    03 UBP received IND approval from Thailand FDA for UB-421 (anti-CD4 mAb) Phase III trial for HAART substitution in HAART stabilized HIV patients.
    01 UBP received an award for its Bioprocess Innovation at the 2018 Asia-Pacific Bioprocess Excellence Award Ceremony.
  • 11 UBP received IND approval from TFDA for UB-421 (anti-CD4 mAb) Phase III trial for HAART substitution in HAART stabilized HIV patients.
    11 UBP was awarded the “Exemplary Biohazard Laboratory Management System” by Taiwan Centers for Disease Control and Prevention (Taiwan CDC).
    09 UBP subsidiary, UBP greater China (Yangzhou) Co., Ltd, UBP-YZ, was established.
    09 UBP received IND approval from TFDA for UB-921 (anti-HER2 mAb) Phase I clinical trial.
    07 UBP entered into strategic partnership with Covance, a global contract research organization (CRO) providing drug preclinical animal testing services.
    06 Filed IND for UB-221(an anti-IgE mAb) Phase I clinical trial for treatment of chronic spontaneous urticaria (CSU) with TFDA.
    06 UBP’s subsidiary, UBP greater China (Shanghai) Co., Ltd, UBP-SH, was established.
    06 UBP received the 2017 “Outstanding Biotechnology Corporation Award” at the BioTaiwan forum.
    04 TFDA approved the phase II trial report of UB-421.
    03 UBP received approval of the multi-nation, multi-center phase III IND from Thailand FDA for UB-421 in HAART substitution trial in HAART stabilized HIV patients.
    03 UBP entered into a strategic partnership with IQVIA, an international leading contract research organization (CRO) providing services in clinical trials.
    02 Phase II trial data of UB-421 was presented at the late breaker session at CROI 2017.
    02 President Dr. Mei-June Liao received the recognition for “Bioprocessing Executive of the Year” at the 2017 Asia-Pacific Bioprocessing Excellence Forum.
    02 UBP won the Advanced Development of Innovative BioMolecules Award at the 2017 Asia-Pacific Bioprocessing Excellence Forum.
    01 Filed IND for UB-421 phase III clinical trial (HAART substitution) in HAART stabilized HIV patients with TFDA.
       
  • 12 Filed IND with TFDA for UB-921 (Anti-HER2 mAb) phase I clinical trial in healthy volunteers.
    12 UBP received certificate of occupancy for its eight-story (20,000 sq meter) headquarter building based in Hukou, Hsinchu county designed for administrative, R&D and large scale protein drug manufacturing activities.
    08 UBP entered into a licensing agreement with UBI US Holdings LLC and UBI IP Holdings, both as subsidiaries of United Biomedical, Inc (UBI), for the exclusive US and ROW (ex-Asia) rights for development and commercialization of UB-421.
       

  • 12 UB-421 for HIV treatment won the 12th National Innovation Prize given by Taiwan Biotechnology Strategic Planning Association.
    11 IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD mAb, was approved by Taiwan Food and Drug Administration (TFDA).
    06 United BioPharma received approval from Taiwan Food and Drug Administration (TFDA) for UB-421 Phase II clinical trial HAART substitution therapy in HAART stabilized HIV patients.
    02 Filed an IND submission of a phase II clinical trial for HAART substitution therapy in HAART stabilized HIV patients, with Taiwan Food and Drug Administration (TFDA).
       
  • 12 UB-421 (an anti CD4 mAb) received Gold Medal for 2014 Pharmaceutical Technology Research and Development, jointly awarded by Ministry of Economic Affairs and Ministry of Health, Taiwan.
    12 Filed an IND submission of a phase I clinical trial for UB-621, an anti-HSV-gD mAb, with Taiwan Food and Drug Administration (TFDA).
    12 United BioPharma Licensed in an a mAb product 8D6 for treatment of Allergic Diseases including Asthma, from Academia Sinica.
    11 Completion of phase IIa clinical trial of UB-421, an anti-CD4 mAb, in treatment of naïve HIV patients.
    09 United BioPharma was selected by Taiwan government’s Industrial Cooperation Program (ICP) as the funding recipient to execute the technology transfer process from GE Healthcare for the Single Use Disposal system in biological manufacturing.
    09/19 United BioPharma was listed on the Taiwan Emerging Stock Market (Stock code: 6471).
    09 Anti-CD4 mAb drug candidate UB-421 won the Gold Medal Prize for Innovative Research and Development given by Taipei City Government in its 2014 Annual Biotechnology Forum for Taipei Biotechnology Award.
    05 Establishment of UBP’s Clinical Research Center at the Hsinchu Biomedical Science Park.
    01/16 UBP held its opening ceremony on the 36th floor Auditorium of Taipei 101 building.
       
  • 10/30 Establishment of a strategic alliance between UBP and Formosa Biomedical Technologies/the Chang-Gun Memorial Hospital of the Formosa Plastic Group.
    09/30 Establishment of United BioPharma (UBP) through spinoff from its parent company United Biomedical, Asia (UBI Asia).